Chimerix (NASDAQ:CMRX) Given “Neutral” Rating at Wedbush

Wedbush reiterated their neutral rating on shares of Chimerix (NASDAQ:CMRX) in a report published on Wednesday morning,RTT News reports. They currently have a $8.55 target price on the biopharmaceutical company’s stock, up from their prior target price of $7.00.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $8.55 price objective (down from $11.00) on shares of Chimerix in a report on Wednesday.

Chimerix Stock Performance

Shares of CMRX stock opened at $8.46 on Wednesday. The stock has a fifty day moving average price of $4.04 and a 200 day moving average price of $2.17. The stock has a market cap of $760.86 million, a PE ratio of -9.00 and a beta of 0.32. Chimerix has a 1 year low of $0.75 and a 1 year high of $8.47.

Insider Activity at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Chimerix

Several institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new position in Chimerix in the fourth quarter valued at $130,000. Two Sigma Investments LP grew its position in Chimerix by 309.1% during the fourth quarter. Two Sigma Investments LP now owns 101,156 shares of the biopharmaceutical company’s stock valued at $352,000 after acquiring an additional 76,430 shares during the period. OMERS ADMINISTRATION Corp purchased a new stake in Chimerix during the fourth quarter valued at about $535,000. Millennium Management LLC grew its position in Chimerix by 6.8% during the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after acquiring an additional 161,795 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new stake in Chimerix during the fourth quarter valued at about $13,124,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.